Effectiveness of concurrent radiation therapy with UFT or TS-1 for T2N0 glottic cancer in Japan.

Authors:

  • 2 November 2007
    • journal article
Abstract
The aim of this retrospective study was to compare concurrent radiation therapy (RT) combined with peroral chemotherapy (UFT or TS-1) with conventional RT for T2N0 glottic cancer. Between 1974 and 2005, 153 patients with T2N0 glottic cancer were treated with radiation alone or radiation combined with peroral (UFT or TS-1) or intravenous chemotherapy. All except one patient were treated with 2 Gy per fraction, 5 fractions per week, totaling 60 Gy; and the remaining patient was treated with 1.8 Gy per fraction, 5 fractions per week, totaling 61.2 Gy. Eighty-three patients were concurrently given UFT, 24 were given TS-1, 23 intravenous chemotherapy (mainly cisplatin; the Pt Group), and 23 had no chemotherapy. The 5-year local control rate was 83.4%. Stratified by RT alone (the RT group) and concurrent chemoradiation therapy (the CCRT group), 5-year local control rates of the RT and CCRT groups were 82.7% and 83.4%, respectively (p=NS). Stratified by chemotherapy regimens of the CCRT group, 3-year local control rates of the UFT, TS-1 and Pt groups were 90.1%, 100.0% and 73.4%, respectively. Concurrent chemoradiation therapy using UFT or TS-1 for T2N0 glottic cancer is one of the standard treatments in Japan. Concurrent use of TS-1 could be a breakthrough treatment for T2N0 glottic cancer.